0

CS1 (SLAMF7, CD319) Is an Effective Immunotherapeutic Target for Multiple Myeloma

Joseph D Malaer, Porunelloor A Mathew

Am J Cancer Res. 2017 Aug 1;7(8):1637-1641.

PMID: 28861320

Abstract:

CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP1448009946 CS1 CS1 1448009-94-6 Price
qrcode

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x